Cell Therapy

For decades, the fundamental understanding of the human immune system relied on a strict division of labor where specific molecules directed the activities of specialized cellular defenders against pathogens and tumors. This biological framework, often referred to as the MHC dichotomy, suggested

The transition from traditional stem cell therapies to more refined exosome-based treatments represents one of the most significant shifts in regenerative medicine during the middle of this decade. While stem cells offer immense healing potential, they carry inherent risks such as unwanted

The 2026 American Association for Cancer Research annual meeting in San Diego stands as a definitive proving ground where South Korean biotechnology firms must transition from theoretical promise to clinical validation. Unlike later-stage conferences such as ASCO or ESMO, the AACR provides a unique

While Chimeric Antigen Receptor (CAR) T-cell therapy has successfully transformed the clinical outlook for patients with liquid cancers, its efficacy against solid tumors remains one of the most significant hurdles in modern oncology. Unlike the accessible environment of the bloodstream, where

Recent breakthroughs in cancer immunology have finally cracked the code on why the body’s most potent defenders often surrender just when the fight against a tumor becomes most critical. For decades, researchers viewed T cell exhaustion as a simple state of fatigue or a loss of energy resulting

The relentless pursuit of highly effective oncological interventions has historically been hampered by the inability of traditional pharmaceutical agents to distinguish accurately between malignant cells and healthy physiological structures. While chemotherapy and systemic radiation have saved